What Do You Expect From Glaucoma Surgery?

Glaucoma can be a difficult condition to manage and is the most frequent cause of irreversible blindness worldwide.1,2 For patients who require surgery, doctors often face the difficult choice between a treatment that provides highly effective IOP reduction or one with a low risk of complications.2

Primary open-angle glaucoma patients and surgeons need a glaucoma device that enables earlier surgical intervention in order to preserve patient vision3,4.

Designed to treat primary open-angle glaucoma, the Health Canada-approved PRESERFLO™ MicroShunt is a tiny, soft, flexible stent that helps your eye drain excess fluid, and may help lower eye pressure and prevent further vision loss.5 PRESERFLO™ MicroShunt will not restore vision already lost to glaucoma.

PRESERFLO™ MicroShunt: A simpler way to manage your glaucoma

Normally, fluid is circulated in the eye to maintain healthy ocular pressure. If fluid does not drain properly, as is the case with glaucoma, it builds up and raises the pressure inside your eye, and may also damage the delicate tissues around it, potentially leading to permanent vision loss. Here are some benefits of the PRESERFLO™ MicroShunt:

Permanent5

PRESERFLO™ MicroShunt is a permanent treatment option for the management of glaucoma to help drain excess fluid out of the eye.

Less Invasive5

PRESERFLO™ MicroShunt is implanted during an outpatient surgical procedure under anesthesia. The procedure is less invasive than traditional glaucoma surgeries and may take less time to complete.

Lowers IOP5

PRESERFLO™ MicroShunt consistently delivers IOP reductions to average ≤ 15 mmHg in multiple clinical studies and real-world experience.

Designed for Safety5

PRESERFLO™ MicroShunt delivers a safer procedure with low rates of post-op interventions.

Why PRESERFLO™ MicroShunt?

Why PRESERFLO™ MicroShunt?

72% of patients were medication-free 12 months after their surgery8
39% less additional surgical visits required 12 months after implantation9

Introducing PRESERFLO™ MicroShunt

Introducing the PRESERFLO™ MicroShunt subconjunctival glaucoma drainage device, made from a uniquely biocompatible, degradation-resistant material called SIBS, that is designed to reduce IOP in patients with primary open-angle glaucoma.5

How does PRESERFLO™ MicroShunt work?

One end of the PRESERFLO™ MicroShunt is inserted in front of the iris, where the excess fluid in the eye resides. The other end is tucked under the clear membrane surrounding the eye to help drain excess fluid. Watch this video to see the full mechanism of action.

What happens
before surgery?

To prepare for surgery with PRESERFLO™ MicroShunt, your surgeon may instruct you to stop taking your usual medications or to begin taking new ones. Be sure to follow instructions accurately and discuss associated risks, safety information, and questions you may have prior to surgery.

For your safety, you should arrange to have someone take you home after surgery.

What happens
after surgery?

In the first week after surgery, you may experience symptoms including:

Blurry vision
Eye redness
Eye swelling

These symptoms should go away. To help the recovery process, your surgeon may prescribe eye drops. Do not rub your eye or perform any strenuous activity, including sports, shortly after surgery.

Hear Directly from Leonard Pinchuk, Creator of PRESERFLOMicroShuntTM

PRESERFLO™ MicroShunt Important Safety Information

Please discuss all the risks with your eye surgeon before your surgery. The typical surgical risks are reactions to medications, eye pain, inflammation, decrease in vision, increased eye pressure, decreased eye pressure, and swelling of the cornea (clear front part of the eye).

You will be monitored by your eye surgeon after surgery to assure your eye pressure is controlled. Additional treatment with medications such as eye drops, or other glaucoma surgery, may be recommended by your eye surgeon if your eye pressure is not controlled.

References

  1. Susanna R et al. Why do people (still) go blind from glaucoma? Trans Vis Sci Tech. 2015;4(2):1. doi: 10.1167/tvst.4.2.1
  2. Jonas JB et al. Glaucoma. Lancet. 2017;390(10108):2183-2193. doi: 10.1016/S0140-6736(17)31469-1
  3. Sadruddin O, Pinchuk L, Angeles R, Palmberg P. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: a review. Eye Vis (Lond). 2019;6:36. doi:10.1186/s40662-019-0162-1.
  4. Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE study. Ophthalmology. 2020;127:52-61. doi:10.1016/j.ophtha.2019.04.034.
  5. Data on file. Santen Inc. 2021.
  6. Pinchuk L, Riss I, Batlle JF, et al. The development of a micro-shunt made from poly(styrene-block-isobutylene-block-styrene) to treat glaucoma. J Biomed Mater Res Part B. 2017;105B:211-221. doi:10.1002/jbm.b.33525.
  7. Stone GW, Ellis SG, Colombo A, et al. Long-term safety and efficacy of paclitaxel-eluting stents: final 5-year analysis from the TAXUS Clinical Trial Program. JACC Cardiovasc Interv. 2011;4:530-542. doi:10.1016/j.jcin.2011.03.005.
  8. Data on file. Santen Inc. 2017.
  9. Data on file. Santen Inc. 2017.